News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Isotechnika Pharma Inc. (ISA.TO)'s Partner Lux Biosciences Completes Enrollment in Phase 3 Uveitis Study


7/9/2012 9:09:10 AM

EDMONTON, Alberta, July 9, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika") announced today that Lux Biosciences, Inc. ("Lux") has completed patient enrollment in its Phase 3 clinical study using voclosporin (branded as Luveniqâ„¢ by Lux) for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability. Lux anticipates that data from the Phase 3 study will be available early in the first quarter of 2013.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES